HB0017 dosing regimens in moderate to severe plaque psoriasis

Phase 2, randomised, double-blind trial of HB0017 in plaque psoriasis (4 arms), sponsored by Huabo Biopharm. Primary endpoints: Proportion of participants achieving at least 90% improvement in Psoriasis Area and Severity Index at 12 weeks and Proportion of participants achieving static Physician's Global Assessment score of 0 or 1 at 12 weeks. Started Oct 2022; status: completed.